Related Experiment Videos
Levamisole in rheumatoid arthritis -- a double-blind study
The Journal of Rheumatology
|May 1, 1980
Summary
Levamisole at 150 mg daily showed significant toxicity and limited clinical benefit for severe rheumatoid arthritis (RA) patients. Lower dosages may reduce side effects, but this trial found the drug too toxic for RA management.
Area of Science:
- Rheumatology
- Clinical Pharmacology
Background:
- Severe rheumatoid arthritis (RA) presents significant challenges in treatment.
- Exploring novel therapeutic agents for RA is crucial.
Purpose of the Study:
- To evaluate the efficacy and safety of levamisole in severe rheumatoid arthritis (RA).
Main Methods:
- A 6-month double-blind trial involving 24 severe RA patients.
- Patients received either levamisole 150 mg daily or placebo, alongside nonsteroidal anti-inflammatory drugs.
- Adverse events and clinical improvement were monitored.
Main Results:
- High incidence of side effects (rashes, GI upset, stomatitis, depression) in the levamisole group.
- Ten patients discontinued the trial, 8 from the levamisole arm.
- Clinical improvement was observed in 3-4 levamisole patients versus 5 placebo patients.
Conclusions:
- Levamisole 150 mg daily demonstrated excessive toxicity for severe RA management.
- The observed side effect profile suggests this dosage is not suitable for RA treatment.
- Lower dosages might be tolerated, but this study highlights significant safety concerns.